EXHIBIT 99.1
CONTACT:
VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
650-934-5200 | | Trout Group
Ian Clements
415-392-3385 |
FOR IMMEDIATE RELEASE
VIVUS to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 8 - VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Dr. Barbara Troupin, Director, Clinical Development, will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco, on Tuesday, May 5, 2007 at 9:45 a.m. Central Europe Time (3:45 a.m. Eastern Time)
A live webcast and 30-day archive of the presentation will be available at http://www.vivus.com.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The investigational pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE(R) is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company’s web site at www.vivus.com.
###
